Synergia and Bolster have secured acquisition financing for Life & Mobility
August 2026 — Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.
Life & Mobility designs, develops and manufactures innovative mobility products that enhance end users’ independence and quality of life. Headquartered in Doetinchem, the Netherlands, the company has grown into one of Europe’s leading players in the premium mobility aids market. Its strong market position is built on in-house research and development (R&D) capabilities, a focus on product quality and user-centric innovation and a differentiated environmental, social and governance (ESG) proposition centered on refurbishment, product longevity and circular mobility solutions.
Our role in the transaction
Oaklins’ debt advisory team in the Netherlands acted as the exclusive debt advisor to Synergia and Bolster. The team arranged a tailored unitranche financing package, provided by Robeco, to support the acquisition and Life & Mobility’s future growth ambitions. The financing process included an extensive lender education phase, which generated significant interest from a broad group of banks and direct lenders and resulted in a highly competitive process. Working closely with Robeco, the sponsors and management, the team negotiated and executed the financing on attractive terms, providing long-term flexibility to support Life & Mobility’s continued growth. The financing process was executed alongside Oaklins’ role as the exclusive sell-side M&A advisor to Life & Mobility’s shareholders, demonstrating Oaklins’ ability to deliver fully integrated corporate finance solutions. The transaction further strengthens the team’s track record in sponsor-backed financing processes in the healthcare sector.
Paul van den Heuvel
Partner, Synergia Capital Partners
Contáctese con el equipo de la transacción
Transacciones relacionadas
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Aprenda másCibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Aprenda másKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Aprenda más